RECORD // Company

Eikon Therapeutics, Inc.

Built 2026-11-22T00:39:10Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (6)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • EIKON THERAPEUTICS, INC. · Ct business · same registered legal name as 'Eikon Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Eikon Therapeutics · Ctgov · exact name match to 'Eikon Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • EIKON THERAPEUTICS, INC. · East licences · same registered legal name as 'Eikon Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • EIKON THERAPEUTICS INC · Epa echo · same registered legal name as 'Eikon Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • EIKON THERAPEUTICS INC. · Epa echo · same registered legal name as 'Eikon Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • EIKON THERAPEUTICS, INC. · Ny corps · same registered legal name as 'Eikon Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001193125-26-456835

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-86,112,0003 months ended 2026-09-3010-Q2026-11-120001193125-26-4568352026-11-22 00:39 UTCReport an error
Cash and cash equivalents$98,482,000at 2026-09-3010-Q2026-11-120001193125-26-4568352026-11-22 00:39 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001861123
Ticker
EIKN
EIN
842807586
CUSIP
282564103
Record ID
sx:sec:0001861123

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

35 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-12SEC EDGAR company profile2026-11-22 00:39 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-12SEC EDGAR company profile2026-11-22 00:39 UTCReport an error
State of incorporationDE2026-11-12SEC EDGAR company profile2026-11-22 00:39 UTCReport an error
Fiscal year end (MMDD)12312026-11-12SEC EDGAR company profile2026-11-22 00:39 UTCReport an error
Business address230 HARRIET TUBMAN WAY, MILLBRAE, CA, 940302026-11-12SEC EDGAR company profile2026-11-22 00:39 UTCReport an error
ExchangesNasdaq2026-11-12SEC EDGAR company profile2026-11-22 00:39 UTCReport an error
Form D total offering amount (D filed 2025-02-28)$399,999,9342025-02-28D2026-11-22 00:39 UTCReport an error
Form D total amount sold (D filed 2025-02-28)$350,700,0372025-02-28D2026-11-22 00:39 UTCReport an error
Form D industry groupBiotechnology2025-02-28D2026-11-22 00:39 UTCReport an error
Form D revenue rangeDecline to Disclose2025-02-28D2026-11-22 00:39 UTCReport an error
Form D date of first sale2025-02-142025-02-28D2026-11-22 00:39 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12)On November 12, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the quarter ended September 30, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 2.02, including Exhibit 99.1, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).…2026-11-12SEC EDGAR 8-K 0001193125-26-456794 (text as filed, excerpt)2026-11-22 00:39 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-26)On October 26, 2026, Eikon Therapeutics, Inc. (the “Company”) issued a press release announcing data from its TeLuRide-005 trial of EIK1001, which were presented at the 2026 European Society for Medical Oncology (ESMO) Congress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in Item 7.01, including Exhibit 99.1, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of…2026-10-26SEC EDGAR 8-K 0001193125-26-430860 (text as filed, excerpt)2026-11-22 00:39 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-26)On October 26, 2026, the Company presented updated data from its TeLuRide-005 trial of EIK1001 at the 2026 ESMO Congress, detailed below. EIK1001 Clinical Update: Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced non-small cell lung cancer (NSCLC) demonstrates potentially durable effect of EIK1001 in combination with standard of care, as well as a tolerability profile supportive of systemic administration in an outpatient setting, a potential key differentiator of EIK1001 from previous TLR7/8 targeted therapies. In TeLuRide-005, 72 participants…2026-10-26SEC EDGAR 8-K 0001193125-26-430860 (text as filed, excerpt)2026-11-22 00:39 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-23)On October 23, 2026, Eikon Therapeutics, Inc. (the “Company”) issued a press release announcing data from its PARP1-selective and WRN helicase programs, which were presented at the 2026 European Society for Medical Oncology Congress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in Item 7.01, including Exhibit 99.1, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of…2026-10-23SEC EDGAR 8-K 0001193125-26-429549 (text as filed, excerpt)2026-11-22 00:39 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-23)On October 23, 2026, the Company presented initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress, detailed below. EIK1003 Clinical Update: Updated data from EIK1003-001 demonstrate that highly selective non-brain-penetrant PARP1 inhibitor EIK1003 as monotherapy (Cohort 1A) was generally well-tolerated across multiple dose levels. In Cohort 1B, EIK1003 in combination with the novel hormonal agent abiraterone is observed to have a favorable tolerability profile with preliminary signs of clinical activity. In Cohort 1C, signals of antitumor activity were observed with EIK1003 in combination with weekly…2026-10-23SEC EDGAR 8-K 0001193125-26-429549 (text as filed, excerpt)2026-11-22 00:39 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-14)On August 13, 2026, Eikon Therapeutics, Inc. updated its corporate presentation. A copy of the updated presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 7.01, including Exhibit 99.1, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration…2026-08-14SEC EDGAR 8-K 0001193125-26-349936 (text as filed, excerpt)2026-11-22 00:39 UTCReport an error
Employer name (as filed)Eikon Therapeutics, Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:39 UTCReport an error
Certified LCAs122026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:39 UTCReport an error
Certified LCAs later withdrawn22026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:39 UTCReport an error
Total worker positions on certified LCAs122026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:39 UTCReport an error
Top job titles (title, LCA count)Biologist (Sr. Research Associate) (2); Lab Data Manager (1); Manager, Software Engineering (1); Manager, Statistical Programming (1); Senior Manager, Data Management (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:39 UTCReport an error
Wage offered, annualized (n, min, median, max)median $146,858 (range $102,378-$213,512, 12 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:39 UTCReport an error
Worksite statesCA; NJ; OR2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:39 UTCReport an error
Plan (pension, plan no. 001)EIKON THERAPEUTICS 401(K) PLAN: 519 participants, assets $46,195,9682025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 00:39 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$65,170,4732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$55,872,5962026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #3 (13F as filed): Foresite Capital Management IV, LLC$25,365,0502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #4 (13F as filed): Merck & Co., Inc.$21,749,9912026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #5 (13F as filed): Foresite Capital Management V, LLC$17,212,7282026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #6 (13F as filed): Capital World Investors$15,346,0692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$12,041,3262026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #8 (13F as filed): EcoR1 Capital, LLC$9,560,5082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$7,270,5922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error
Largest institutional holder #10 (13F as filed): BAKER BROS. ADVISORS LP$7,249,9932026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:39 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.